American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2015 Jun 24

PMID 26101248

Citations 320

Authors

Lowell E Schnipper

Nancy E Davidson

Dana S Wollins

Courtney Tyne

Douglas W Blayney

Diane Blum

Adam P Dicker

Patricia A Ganz

J Russell Hoverman

Robert Langdon

Gary H Lyman

Neal J Meropol

Therese Mulvey

Lee Newcomer

Jeffrey Peppercorn

Blase Polite

Derek Raghavan

Gregory Rossi

Leonard Saltz

Deborah Schrag

Thomas J Smith

Peter P Yu

Clifford A Hudis

Richard L Schilsky

American Society of Clinical Oncology

Affiliations

Soon will be listed here.

Citing Articles

Prevalence and Predictors of Medical Mistrust Among Socioeconomically and Racially Diverse Cancer Patients in Philadelphia.

Hall M, Park C, Ruth K, Kelly P, Singley K, Luck C Cancers (Basel). 2025; 17(4).

PMID: 40002244 PMC: 11853404. DOI: 10.3390/cancers17040649.

Synthesis and application of diazenyl sulfonamide-based schiff bases as potential BRCA2 active inhibitors against MCF-7 breast cancer cell line.

Rezaeianzadeh O, Asghari S, Tajbakhsh M, Khalilpour A, Shityakov S Sci Rep. 2025; 15(1):6661.

PMID: 39994448 PMC: 11850876. DOI: 10.1038/s41598-025-91113-w.

Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study.

Guzzinati S, Andreotti A, Lopez T, Gori S, Gagliani A, Mallone S PLoS One. 2025; 20(2):e0318849.

PMID: 39951441 PMC: 11828425. DOI: 10.1371/journal.pone.0318849.

Osanto S, Vliert-Bout A, Gomez de Segura C, Efficace F, Sparano F, Willemse P EClinicalMedicine. 2024; 78:102914.

PMID: 39619239 PMC: 11605133. DOI: 10.1016/j.eclinm.2024.102914.

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice.

Tomonari T, Tani J, Sato Y, Tanaka H, Morishita A, Okamoto K JGH Open. 2024; 8(10):e70033.

PMID: 39371045 PMC: 11450737. DOI: 10.1002/jgh3.70033.

References

Zafar S, McNeil R, Thomas C, Lathan C, Ayanian J, Provenzale D . Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2014; 11(2):145-50. PMC: 4371118. DOI: 10.1200/JOP.2014.001542. View

Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K . Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013; 32(6):1143-52. PMC: 4240626. DOI: 10.1377/hlthaff.2012.1263. View

Weinstein M, Torrance G, McGuire A . QALYs: the basics. Value Health. 2009; 12 Suppl 1:S5-9. DOI: 10.1111/j.1524-4733.2009.00515.x. View

Stinnett A, Mullahy J . Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998; 18(2 Suppl):S68-80. DOI: 10.1177/0272989X98018002S09. View

San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-17. DOI: 10.1056/NEJMoa0801479. View

Zafar S, Abernethy A . Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park). 2013; 27(2):80-1, 149. PMC: 4523887. View

Weeks J, Catalano P, Cronin A, Finkelman M, Mack J, Keating N . Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367(17):1616-25. PMC: 3613151. DOI: 10.1056/NEJMoa1204410. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Schnipper L, Lyman G, Blayney D, Hoverman J, Raghavan D, Wollins D . American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013; 31(34):4362-70. DOI: 10.1200/JCO.2013.53.3943. View

10.

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

11.

Morgan S, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P . Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom. Health Aff (Millwood). 2006; 25(2):337-47. DOI: 10.1377/hlthaff.25.2.337. View

12.

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View

13.

Ellis L, Bernstein D, Voest E, Berlin J, Sargent D, Cortazar P . American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014; 32(12):1277-80. DOI: 10.1200/JCO.2013.53.8009. View

14.

Streeter S, Schwartzberg L, Husain N, Johnsrud M . Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011; 7(3 Suppl):46s-51s. PMC: 3092458. DOI: 10.1200/JOP.2011.000316. View

15.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

16.

Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M . Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001; 357(9267):1478-84. DOI: 10.1016/S0140-6736(00)04644-4. View

17.

Ubel P . Beyond costs and benefits: understanding how patients make health care decisions. Oncologist. 2010; 15 Suppl 1:5-10. DOI: 10.1634/theoncologist.2010-S1-5. View

18.

Mariotto A, Yabroff K, Shao Y, Feuer E, Brown M . Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103(2):117-28. PMC: 3107566. DOI: 10.1093/jnci/djq495. View

19.

Meropol N, Schrag D, Smith T, Mulvey T, Langdon Jr R, Blum D . American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009; 27(23):3868-74. DOI: 10.1200/JCO.2009.23.1183. View

20.

Schnipper L, Smith T, Raghavan D, Blayney D, Ganz P, Mulvey T . American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012; 30(14):1715-24. DOI: 10.1200/JCO.2012.42.8375. View